Influence of Spironolactone and Its Metabolite Canrenone on Serum Digoxin Assays
- 1 January 1990
- journal article
- research article
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 12 (1), 82-84
- https://doi.org/10.1097/00007691-199001000-00015
Abstract
Although current immunoassay kits for digoxin supposedly have antibodies of high specificity, serum digoxin levels in patients taking spironolactone suggest that spironolactone interferes with the determination. In vitro determinations of digoxin performed on blank serum spiked with spironolactone and its metabolite canrenone showed that contrary to the belief gained from reading the manuals of some diagnostic immunoassay kits, spironolactone significantly influences digoxin determinations.This publication has 4 references indexed in Scilit:
- The effect of renal and hepatic impairment and of spironolactone on digoxin immunoassaysEuropean Journal of Clinical Pharmacology, 1988
- Spironolactone as a Source of Interference in Commercial Digoxin ImmunoassaysTherapeutic Drug Monitoring, 1987
- New insights into the pharmacokinetics of spironolactoneClinical Pharmacology & Therapeutics, 1985
- Spironolactone-associated digoxin radioimmunoassay interference.Clinical Chemistry, 1979